Citigroup upgrades Bio-Techne to Buy with a new PT of $70.
PorAinvest
jueves, 21 de agosto de 2025, 8:48 am ET1 min de lectura
C--
The upgrade follows a significant increase in Citigroup's stake in Bio-Techne. According to its latest Form 13F filing with the Securities and Exchange Commission, Citigroup boosted its position by 131.1% during the first quarter, acquiring an additional 171,863 shares to total 302,927 shares [2].
Bio-Techne's recent earnings report also demonstrated strong performance. The company reported $0.53 earnings per share for the quarter, beating the consensus estimate by $0.03. Revenue for the quarter was $316.96 million, up 3.6% year-over-year. The company's return on equity was 13.43%, and its net margin was 6.02% [2].
In addition to Citigroup's upgrade, several other analysts have also shown optimism towards Bio-Techne. UBS Group, Stephens, and TD Cowen have all set "buy" ratings with varying price targets, while Royal Bank of Canada has set a "sector perform" rating. Despite these positive ratings, Bio-Techne currently has an average rating of "Moderate Buy" and an average price target of $69.42 [2].
The company's stock has seen a steady increase in recent months, trading up $0.35 during midday trading on Monday, July 2, 2025, to hit $53.95. The stock's fifty-day moving average is $52.72, and its 200-day moving average is $55.17 [2].
Bio-Techne's strong financial performance and positive analyst ratings suggest that the company is well-positioned for future growth. The recent upgrades and increased institutional investment could further drive the stock's performance.
References:
[1] https://www.marketscreener.com/news/analyst-recommendations-coreweave-coty-marvell-snap-amda--ce7c51d3dc8bf327
[2] https://www.marketbeat.com/instant-alerts/filing-citigroup-inc-buys-171863-shares-of-bio-techne-corp-nasdaqtech-2025-08-14/
TECH--
Citigroup upgrades Bio-Techne to Buy with a new PT of $70.
Citigroup has recently upgraded its recommendation for Bio-Techne Corporation (NASDAQ: TECH) to "Buy" and raised the price target to $70. This move comes amidst a series of analyst upgrades and institutional investments in the biotechnology company.The upgrade follows a significant increase in Citigroup's stake in Bio-Techne. According to its latest Form 13F filing with the Securities and Exchange Commission, Citigroup boosted its position by 131.1% during the first quarter, acquiring an additional 171,863 shares to total 302,927 shares [2].
Bio-Techne's recent earnings report also demonstrated strong performance. The company reported $0.53 earnings per share for the quarter, beating the consensus estimate by $0.03. Revenue for the quarter was $316.96 million, up 3.6% year-over-year. The company's return on equity was 13.43%, and its net margin was 6.02% [2].
In addition to Citigroup's upgrade, several other analysts have also shown optimism towards Bio-Techne. UBS Group, Stephens, and TD Cowen have all set "buy" ratings with varying price targets, while Royal Bank of Canada has set a "sector perform" rating. Despite these positive ratings, Bio-Techne currently has an average rating of "Moderate Buy" and an average price target of $69.42 [2].
The company's stock has seen a steady increase in recent months, trading up $0.35 during midday trading on Monday, July 2, 2025, to hit $53.95. The stock's fifty-day moving average is $52.72, and its 200-day moving average is $55.17 [2].
Bio-Techne's strong financial performance and positive analyst ratings suggest that the company is well-positioned for future growth. The recent upgrades and increased institutional investment could further drive the stock's performance.
References:
[1] https://www.marketscreener.com/news/analyst-recommendations-coreweave-coty-marvell-snap-amda--ce7c51d3dc8bf327
[2] https://www.marketbeat.com/instant-alerts/filing-citigroup-inc-buys-171863-shares-of-bio-techne-corp-nasdaqtech-2025-08-14/
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema
Comentarios
Aún no hay comentarios